Carfilzomib Versus Bortezomib In Combination With Cyclophosphamide And Dexamethasone For Treatment Of First Relapse Or Primary Refractory Multiple Myeloma (Mm): Outcomes Based On Genetic Risk And Long Term Follow Up Of The Phase 2 Muk Five Study
BLOOD(2018)
摘要
Background
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要